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Background: High-risk patients (pts) may need combination therapy to reach LDL-C targets. The current study evaluated the efficacy of 
rosuvastatin (R)+ezetimibe (E) vs simvastatin (S)+E.
Methods: GRAVITY (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY), an open-label, randomized 
study, examined the efficacy and safety of R10 or 20mg+E10mg vs S40 or 80mg+E10mg in pts with elevated LDL-C (130-220mg/dL), TG <400mg/
dL and CHD (or risk equivalent). After a 6-wk dietary lead-in and washout of lipid-lowering drugs, pts received R10mg, R20mg, S40mg, or S80mg 
monotherapy for 6 wks. E10mg was then added to each regimen for a further 6 wks. Primary outcome was % change from baseline LDL-C at wk 12.
Results: R20mg+E10mg produced greater reductions in LDL-C and improvements in other lipid parameters vs S40mg+E10mg or S80mg+E10mg. 
R10mg+E10mg significantly reduced LDL-C, TG, non-HDL-C, and Apo-B compared with S40mg+E10mg. More pts achieved NCEP ATP III LDL-C goals 
of <100mg/dL and <70mg/dL with R20mg+E10mg than with S40mg+E10mg or S80mg+E10mg, and of <100mg/dL with R10mg+E10mg than with 
S40mg+E10mg. All treatments were well tolerated. One case of myopathy occurred during S80mg monotherapy. 
Study Group R10mg+E10mg(N=210)
R20mg+E10mg
(N=204)
S40mg+E10mg
(N=199)
S80mg+E10mg
(N=201)
Baseline LDL-C (mg/dL; 
mean±SD) 162.7±22.7 164.8±24.7 164.8±23.6 163.1±24.1
Mean % change from baseline LDL-C -59.7* -63.5† § -55.2 -57.4
HDL-C 6.4 7.5* ‡ 3.9 4.3
TG -28.9* -35.0† § -23.0 -25.8
Non-HDL-C -54.7† -58.9† § -49.9 -52.4
Apo-B -46.1* -49.5† § -42.0 -44.2
% of pts achieving LDL-C goals <100 mg/dL 93.3* 95.6† ‡ 87.4 88.6
<70 mg/dL 67.1 77.0† § 55.3 67.7
*p<0.05 vs
S40mg+E10mg; †p<0.001 vs 
S40mg+E10mg
†p<0.001 vs 
S40mg+E10mg; ‡p<0.05 
vs S80mg+E10mg; 
§p<0.001 vs 
S80mg+E10mg
Conclusion: R20mg+E10mg produced greater reductions in LDL-C, non-HDL-C and Apo-B, and more pts achieved LDL-C goals than with 
S40mg+E10mg or S80mg+E10mg. R10mg+E10mg had superior lipid-lowering efficacy and more pts achieved LDL-C <100mg/dL compared with 
S40mg+E10mg.
